{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:41:32Z","timestamp":1788302492147,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ophtha.2019.12.031","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T11:21:46Z","timestamp":1579260106000},"page":"963-976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":218,"title":["Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-8441","authenticated-orcid":false,"given":"Quan Dong","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arup","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin U.","family":"Dugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1031-7488","authenticated-orcid":false,"given":"Carolyn K.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir J.","family":"Sepah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0589-4384","authenticated-orcid":false,"given":"Heather","family":"MacLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2019.12.031_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ophtha.2019.12.031_bib2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2019.12.031_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/2333721418801601","article-title":"The impact of age-related macular degeneration on quality of life and its association with demographic data: results from the NEI VFQ-25 Questionnaire in a Norwegian population","volume":"4","author":"Schippert","year":"2018","journal-title":"Gerontol Geriatr Med"},{"key":"10.1016\/j.ophtha.2019.12.031_bib4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib5","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/CIA.S143508","article-title":"Recent developments in age-related macular degeneration: a review","volume":"12","author":"Al-Zamil","year":"2017","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.ophtha.2019.12.031_bib6","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1172\/JCI71029","article-title":"Recent developments in the treatment of age-related macular degeneration","volume":"124","author":"Holz","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ophtha.2019.12.031_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"issue":"2-a Suppl","key":"10.1016\/j.ophtha.2019.12.031_bib8","first-page":"S3","article-title":"Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration","volume":"24","author":"Wykoff","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ophtha.2019.12.031_bib9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.survophthal.2017.03.004","article-title":"Retinal pigment epithelium tears: classification, pathogenesis, predictors, and management","volume":"62","author":"Ersoz","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.oret.2016.09.001","article-title":"Visual and morphologic outcomes in eyes with hard exudate in the comparison of age-related macular degeneration treatments trials","volume":"1","author":"Daniel","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2019.12.031_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.mam.2012.04.005","article-title":"Understanding age-related macular degeneration (AMD): relationships between the photoreceptor\/retinal pigment epithelium\/Bruch's membrane\/choriocapillaris complex","volume":"33","author":"Bhutto","year":"2012","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.ophtha.2019.12.031_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196481","article-title":"Visual acuity and contrast sensitivity are two important factors affecting vision-related quality of life in advanced age-related macular degeneration","volume":"13","author":"Roh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2019.12.031_bib13","first-page":"109","article-title":"Race, iris color, and age-related macular degeneration","volume":"98","author":"Frank","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2019.12.031_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1477-7525-4-97","article-title":"Quality of life in age-related macular degeneration: a review of the literature","volume":"4","author":"Mitchell","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ophtha.2019.12.031_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1475-1313.2011.00848.x","article-title":"Depressive symptoms and quality of life in people with age- related macular degeneration","volume":"31","author":"Mathew","year":"2011","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.ophtha.2019.12.031_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0167-4943(99)00045-X","article-title":"Sleep, health and visual impairment in the elderly","volume":"30","author":"Asplund","year":"2000","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.ophtha.2019.12.031_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archopht.116.4.514","article-title":"The psychosocial impact of macular degeneration","volume":"116","author":"Williams","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"10S","key":"10.1016\/j.ophtha.2019.12.031_bib18","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.ophtha.2016.04.056","article-title":"Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside","volume":"123","author":"Campochiaro","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.12.031_bib19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.120.3.338","article-title":"Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment","volume":"120","author":"Krzystolik","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jcp.10246","article-title":"VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier","volume":"195","author":"Saishin","year":"2003","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib21","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ophtha.2019.12.031_bib22","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2019.12.031_bib23","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2019.12.031_bib24","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2019.12.031_bib25","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.12.031_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","article-title":"Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study","volume":"197","author":"Liu","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib27","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.12.031_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40942-016-0026-y","article-title":"Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept","volume":"2","author":"de Oliveira Dias","year":"2016","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.ophtha.2019.12.031_bib29","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2217\/cer-2018-0058","article-title":"The economic and humanistic burden of patients in receipt of current available therapies for nAMD","volume":"7","author":"Jaffe","year":"2018","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.ophtha.2019.12.031_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OPTH.S151611","article-title":"Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients","volume":"12","author":"Ehlken","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib31","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib32","unstructured":"Gaudreault J, Gunde T, Floyd H, et\u00a0al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Poster presented at: The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 6-10, 2012, Fort Lauderdale, Florida."},{"key":"10.1016\/j.ophtha.2019.12.031_bib33","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.12.031_bib34","unstructured":"Tietz J, Spohn G, Schmid G, et\u00a0al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor A for the treatment of retinal disorders. Poster presented at: The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 3-7, 2015, Denver, Colorado."},{"key":"10.1016\/j.ophtha.2019.12.031_bib35","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0014-5793(01)03101-5","article-title":"Antigen-independent selection of stable intracellular single-chain antibodies","volume":"508","author":"Auf der Maur","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ophtha.2019.12.031_bib36","unstructured":"Escher D, Schmidt A, Steiner P, et\u00a0al. Single-chain antibody fragments in ophthalmology. Poster presented at: European Society of Retina Specialists (EURETINA) 15th Congress, September 17-20, 2015, Nice, France."},{"key":"10.1016\/j.ophtha.2019.12.031_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2249.2002.01808.x","article-title":"Penetration of engineered antibody fragments into the eye","volume":"128","author":"Thiel","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3389\/fimmu.2017.00653","article-title":"Camelid single-domain antibodies as an alternative to overcome challenges related to the prevention, detection, and control of neglected tropical diseases","volume":"8","author":"Fernandes","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib39","first-page":"3402","article-title":"Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms","volume":"52","author":"Yokota","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.ophtha.2019.12.031_bib40","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.1074\/jbc.M109.072876","article-title":"Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies","volume":"285","author":"Borras","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ophtha.2019.12.031_bib41","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2019.12.031_bib42","unstructured":"Nimz EL, Van\u2019t Land CW, Y\u00e1\u00f1ez JA, Chastain JE. Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates. Poster presented at: The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 1-5, 2016, Seattle, Washington."},{"key":"10.1016\/j.ophtha.2019.12.031_bib43","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2019.12.031_bib44","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF TRAP","volume":"92","author":"Stewart","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib45","unstructured":"Berger B, Yanni S, Wenzel A, et\u00a0al. Efficacy of RTH258 (ESBA1008), an anti-VEGF agent, applied by microvolume injection or infusion in subjects with neovascular AMD. Poster presented at: The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 3-7, 2015, Denver, Colorado."},{"key":"10.1016\/j.ophtha.2019.12.031_bib46","first-page":"72","article-title":"A\u00a0novel compound for treatment of wet AMD","author":"Chexal","year":"2016","journal-title":"Retina Today"},{"key":"10.1016\/j.ophtha.2019.12.031_bib47","unstructured":"Berger B, Weichselberger A, Schmidt W, et\u00a0al. Microvolume drug delivery: a novel therapeutic strategy for patients with neovascular age-related macular degeneration (nAMD). Poster presented at: The 48th Annual Scientific Meeting of the Retina Society; October 7-11, 2015, Paris, France."},{"key":"10.1016\/j.ophtha.2019.12.031_bib48","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.12.031_bib49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.12.031_bib50","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/eye.2016.18","article-title":"Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis","volume":"30","author":"Baxter","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2019.12.031_bib51","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ophtha.2015.12.001","article-title":"Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment","volume":"123","author":"Mueller","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.12.031_bib52","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1097\/IAE.0000000000002299","article-title":"Twelve-month outcomes of intravitreal aflibercept for neovascular age-related macular degeneration: fixed versus as-needed dosing","volume":"39","author":"Veritti","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2019.12.031_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","article-title":"The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration-a Phase IV randomised clinical trial with ranibizumab: The FLUID study","volume":"16","author":"Arnold","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib54","series-title":"EYLEA\u00ae (aflibercept) Injection for Intravitreal Injection [Prescribing Information]","year":"2019"},{"key":"10.1016\/j.ophtha.2019.12.031_bib55","series-title":"Regeneron announces FDA acceptance of sBLA filing for 12-week dosing of EYLEA\u00ae (aflibercept) injection for patients with wet AMD [press release]","year":"2017"},{"key":"10.1016\/j.ophtha.2019.12.031_bib56","series-title":"FDA approves EYLEA\u00ae (aflibercept) injection sBLA in wet age-related macular degeneration [press release]","year":"2018"},{"key":"10.1016\/j.ophtha.2019.12.031_bib57","series-title":"EYLEA [Summary of Product Characteristics]","year":"2017"},{"key":"10.1016\/j.ophtha.2019.12.031_bib58","first-page":"561","article-title":"Intravitreal ziv-aflibercept: Clinical effects and economic impact","volume":"6","author":"Singh","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.ophtha.2019.12.031_bib59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/eye.2017.187","article-title":"Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study","volume":"32","author":"Cui","year":"2018","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2019.12.031_bib60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CIA.S151225","article-title":"Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis","volume":"13","author":"Cui","year":"2018","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.ophtha.2019.12.031_bib61","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1097\/IAE.0000000000002152","article-title":"Conbercept in patients with treatment-naive neovascular age-related macular degeneration in real-life setting in China","volume":"39","author":"Li","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2019.12.031_bib62","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12886-018-0807-1","article-title":"Conbercept for patients with age-related macular degeneration: a systematic review","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.12.031_bib63","series-title":"New STAIRWAY study data shows potential for extended durability with Roche\u2019s faricimab in neovascular age-related macular degeneration (nAMD) [press release]","year":"2018"},{"issue":"10","key":"10.1016\/j.ophtha.2019.12.031_bib64","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1089\/jop.2018.0062","article-title":"Double-masked, randomized, phase 2 evaluation of abicipar pegol (an anti-VEGF darpin therapeutic) in neovascular age-related macular degeneration","volume":"34","author":"Callanan","year":"2018","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2019.12.031_bib65","series-title":"Allergan and Molecular Partners announce two positive phase 3 clinical trials for abicipar pegol 8 and 12-week regimens for the treatment in patients with neovascular age-related macular degeneration [press release]","year":"2018"},{"key":"10.1016\/j.ophtha.2019.12.031_bib66","series-title":"Allergan and Molecular Partners announce topline safety results from MAPLE study of abicipar pegol [press release]","year":"2019"},{"key":"10.1016\/j.ophtha.2019.12.031_bib67","series-title":"Genentech unveils positive phase II results for the port delivery system with ranibizumab (PDS), the first-ever eye implant to achieve sustained delivery of a biologic medicine to treat people with wet age-related macular degeneration (AMD) [press release]","year":"2018"},{"key":"10.1016\/j.ophtha.2019.12.031_bib68","article-title":"Sustained delivery system intended to ease AMD treatment burden","author":"Regillo","year":"2018","journal-title":"Ocular Surgery News"},{"key":"10.1016\/j.ophtha.2019.12.031_bib69","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ajo.2014.05.014","article-title":"Anti-VEGF treatment patterns for neovascular age-related macular degeneration among Medicare beneficiaries","volume":"158","author":"Lad","year":"2014","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020300415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020300415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:08:48Z","timestamp":1758982128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642020300415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0161642020300415"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.12.031","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}